CRDF: Settlement enables global phase III launch for onvansertib in RAS-mutated mCRC, pending funding
A settlement with Nerviano secures exclusive rights and extends royalty terms for onvansertib, which is advancing to a global phase III trial in first-line RAS-mutated metastatic colorectal cancer. The trial targets 640 patients, with accelerated approval possible based on ORR, and is expected to s…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.